1. Diab DL, Watts NB. Secondary osteoporosis: differential diagnosis and workup. Clin Obstet Gynecol. 2013; 56:686–693.
2. Painter SE, Kleerekoper M, Camacho PM. Secondary osteoporosis: a review of the recent evidence. Endocr Pract. 2006; 12:436–445.
Article
3. Cerda Gabaroi D, Peris P, Monegal A, Albaladejo C, Martinez MA, Muxi A, et al. Search for hidden secondary causes in postmenopausal women with osteoporosis. Menopause. 2010; 17:135–139.
4. Emkey GR, Epstein S. Secondary osteoporosis: pathophysiology & diagnosis. Best Pract Res Clin Endocrinol Metab. 2014; 28:911–935.
5. Nieman LK. Approach to the patient with an adrenal incidentaloma. J Clin Endocrinol Metab. 2010; 95:4106–4113.
Article
6. Arnaldi G, Boscaro M. Adrenal incidentaloma. Best Pract Res Clin Endocrinol Metab. 2012; 26:405–419.
Article
7. Favier J, Amar L, Gimenez-Roqueplo AP. Paraganglioma and phaeochromocytoma: from genetics to personalized medicine. Nat Rev Endocrinol. 2015; 11:101–111.
Article
8. Prejbisz A, Lenders JW, Eisenhofer G, Januszewicz A. Mortality associated with phaeochromocytoma. Horm Metab Res. 2013; 45:154–158.
Article
9. Vilela LAP, Almeida MQ. Diagnosis and management of primary aldosteronism. Arch Endocrinol Metab. 2017; 61:305–312.
Article
10. Prejbisz A, Warchol-Celinska E, Lenders JW, Januszewicz A. Cardiovascular risk in primary hyperaldosteronism. Horm Metab Res. 2015; 47:973–980.
Article
11. De Leo M, Pivonello R, Auriemma RS, Cozzolino A, Vitale P, Simeoli C, et al. Cardiovascular disease in Cushing's syndrome: heart versus vasculature. Neuroendocrinology. 2010; 92:Suppl 1. 50–54.
Article
12. Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int. 2007; 18:1319–1328.
Article
13. Rizzoli R, Biver E. Glucocorticoid-induced osteoporosis: who to treat with what agent? Nat Rev Rheumatol. 2015; 11:98–109.
Article
14. Weinstein RS. Clinical practice. Glucocorticoid-induced bone disease. N Engl J Med. 2011; 365:62–70.
15. Compston J. Management of glucocorticoid-induced osteoporosis. Nat Rev Rheumatol. 2010; 6:82–88.
Article
16. Rizzoli R, Adachi JD, Cooper C, Dere W, Devogelaer JP, Diez-Perez A, et al. Management of glucocorticoid-induced osteoporosis. Calcif Tissue Int. 2012; 91:225–243.
Article
17. Kajimura D, Hinoi E, Ferron M, Kode A, Riley KJ, Zhou B, et al. Genetic determination of the cellular basis of the sympathetic regulation of bone mass accrual. J Exp Med. 2011; 208:841–851.
Article
18. Bonnet N, Laroche N, Vico L, Dolleans E, Benhamou CL, Courteix D. Dose effects of propranolol on cancellous and cortical bone in ovariectomized adult rats. J Pharmacol Exp Ther. 2006; 318:1118–1127.
Article
19. Kondo H, Togari A. Continuous treatment with a low-dose β-agonist reduces bone mass by increasing bone resorption without suppressing bone formation. Calcif Tissue Int. 2011; 88:23–32.
Article
20. Takeda S, Elefteriou F, Levasseur R, Liu X, Zhao L, Parker KL, et al. Leptin regulates bone formation via the sympathetic nervous system. Cell. 2002; 111:305–317.
Article
21. Toulis KA, Hemming K, Stergianos S, Nirantharakumar K, Bilezikian JP. β-Adrenergic receptor antagonists and fracture risk: a meta-analysis of selectivity, gender, and site-specific effects. Osteoporos Int. 2014; 25:121–129.
Article
22. Schlienger RG, Kraenzlin ME, Jick SS, Meier CR. Use of beta-blockers and risk of fractures. JAMA. 2004; 292:1326–1332.
23. Reid IR, Lucas J, Wattie D, Horne A, Bolland M, Gamble GD, et al. Effects of a beta-blocker on bone turnover in normal postmenopausal women: a randomized controlled trial. J Clin Endocrinol Metab. 2005; 90:5212–5216.
24. Bonnet N, Gadois C, McCloskey E, Lemineur G, Lespessailles E, Courteix D, et al. Protective effect of beta blockers in postmenopausal women: influence on fractures, bone density, micro and macroarchitecture. Bone. 2007; 40:1209–1216.
25. de Vries F, Souverein PC, Cooper C, Leufkens HG, van Staa TP. Use of beta-blockers and the risk of hip/femur fracture in the United Kingdom and The Netherlands. Calcif Tissue Int. 2007; 80:69–75.
26. Veldhuis-Vlug AG, Tanck MW, Limonard EJ, Endert E, Heijboer AC, Lips P, et al. The effects of beta-2 adrenergic agonist and antagonist on human bone metabolism: a randomized controlled trial. Bone. 2015; 71:196–200.
Article
27. de Vries F, Pouwels S, Bracke M, Leufkens HG, Cooper C, Lammers JW, et al. Use of beta-2 agonists and risk of hip/femur fracture: a population-based case-control study. Pharmacoepidemiol Drug Saf. 2007; 16:612–619.
Article
28. Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk in patients with chronic lung diseases treated with bronchodilator drugs and inhaled and oral corticosteroids. Chest. 2007; 132:1599–1607.
Article
29. Gonnelli S, Caffarelli C, Maggi S, Guglielmi G, Siviero P, Rossi S, et al. Effect of inhaled glucocorticoids and beta(2) agonists on vertebral fracture risk in COPD patients: the EOLO study. Calcif Tissue Int. 2010; 87:137–143.
30. Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. Lancet. 2005; 366:665–675.
Article
31. Veldhuis-Vlug AG, El Mahdiui M, Endert E, Heijboer AC, Fliers E, Bisschop PH. Bone resorption is increased in pheochromocytoma patients and normalizes following adrenalectomy. J Clin Endocrinol Metab. 2012; 97:E2093–E2097.
Article
32. Kim BJ, Kwak MK, Ahn SH, Kim H, Lee SH, Song KH, et al. Lower bone mass and higher bone resorption in pheochromocytoma: importance of sympathetic activity on human bone. J Clin Endocrinol Metab. 2017; 102:2711–2718.
Article
33. Elefteriou F, Ahn JD, Takeda S, Starbuck M, Yang X, Liu X, et al. Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature. 2005; 434:514–520.
Article
34. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 1996; 312:1254–1259.
Article
35. Johnell O, Oden A, De Laet C, Garnero P, Delmas PD, Kanis JA. Biochemical indices of bone turnover and the assessment of fracture probability. Osteoporos Int. 2002; 13:523–526.
Article
36. Garnero P, Hausherr E, Chapuy MC, Marcelli C, Grandjean H, Muller C, et al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res. 1996; 11:1531–1538.
Article
37. Young WF. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol (Oxf). 2007; 66:607–618.
Article
38. Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016; 101:1889–1916.
Article
39. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005; 45:1243–1248.
Article
40. Salcuni AS, Palmieri S, Carnevale V, Morelli V, Battista C, Guarnieri V, et al. Bone involvement in aldosteronism. J Bone Miner Res. 2012; 27:2217–2222.
Article
41. Wu VC, Chang CH, Wang CY, Lin YH, Kao TW, Lin PC, et al. Risk of fracture in primary aldosteronism: a population-based cohort study. J Bone Miner Res. 2017; 32:743–752.
Article
42. Notsu M, Yamauchi M, Yamamoto M, Nawata K, Sugimoto T. Primary aldosteronism as a risk factor for vertebral fracture. J Clin Endocrinol Metab. 2017; 102:1237–1243.
Article
43. Silva BC, Leslie WD, Resch H, Lamy O, Lesnyak O, Binkley N, et al. Trabecular bone score: a noninvasive analytical method based upon the DXA image. J Bone Miner Res. 2014; 29:518–530.
Article
44. Bousson V, Bergot C, Sutter B, Levitz P, Cortet B. Scientific Committee of the Groupe de Recherche et d'Information sur les Osteoporoses. Trabecular bone score (TBS): available knowledge, clinical relevance, and future prospects. Osteoporos Int. 2012; 23:1489–1501.
Article
45. Boutroy S, Hans D, Sornay-Rendu E, Vilayphiou N, Winzenrieth R, Chapurlat R. Trabecular bone score improves fracture risk prediction in non-osteoporotic women: the OFELY study. Osteoporos Int. 2013; 24:77–85.
Article
46. Iki M, Tamaki J, Kadowaki E, Sato Y, Dongmei N, Winzenrieth R, et al. Trabecular bone score (TBS) predicts vertebral fractures in Japanese women over 10 years independently of bone density and prevalent vertebral deformity: the Japanese Population-Based Osteoporosis (JPOS) cohort study. J Bone Miner Res. 2014; 29:399–407.
Article
47. Silva BC, Broy SB, Boutroy S, Schousboe JT, Shepherd JA, Leslie WD. Fracture risk prediction by non-BMD DXA measures: the 2015 ISCD Official Positions Part 2: trabecular bone score. J Clin Densitom. 2015; 18:309–330.
Article
48. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes: a meta-analysis. Osteoporos Int. 2007; 18:427–444.
49. Kim JH, Choi HJ, Ku EJ, Kim KM, Kim SW, Cho NH, et al. Trabecular bone score as an indicator for skeletal deterioration in diabetes. J Clin Endocrinol Metab. 2015; 100:475–482.
Article
50. Leslie WD, Aubry-Rozier B, Lamy O, Hans D. Manitoba Bone Density Program. TBS (trabecular bone score) and diabetes-related fracture risk. J Clin Endocrinol Metab. 2013; 98:602–609.
Article
51. Kim BJ, Kwak MK, Ahn SH, Kim H, Lee SH, Koh JM. Lower trabecular bone score in patients with primary aldosteronism: human skeletal deterioration by aldosterone excess. J Clin Endocrinol Metab. 2018; 103:615–621.
Article
52. Asaba Y, Ito M, Fumoto T, Watanabe K, Fukuhara R, Takeshita S, et al. Activation of renin-angiotensin system induces osteoporosis independently of hypertension. J Bone Miner Res. 2009; 24:241–250.
Article
53. Shimizu H, Nakagami H, Osako MK, Hanayama R, Kunugiza Y, Kizawa T, et al. Angiotensin II accelerates osteoporosis by activating osteoclasts. FASEB J. 2008; 22:2465–2475.
Article
54. Beavan S, Horner A, Bord S, Ireland D, Compston J. Colocalization of glucocorticoid and mineralocorticoid receptors in human bone. J Bone Miner Res. 2001; 16:1496–1504.
Article
55. Pilz S, Kienreich K, Drechsler C, Ritz E, Fahrleitner-Pammer A, Gaksch M, et al. Hyperparathyroidism in patients with primary aldosteronism: cross-sectional and interventional data from the GECOH study. J Clin Endocrinol Metab. 2012; 97:E75–E79.
Article
56. Petramala L, Zinnamosca L, Settevendemmie A, Marinelli C, Nardi M, Concistre A, et al. Bone and mineral metabolism in patients with primary aldosteronism. Int J Endocrinol. 2014; 2014:836529.
Article
57. Ceccoli L, Ronconi V, Giovannini L, Marcheggiani M, Turchi F, Boscaro M, et al. Bone health and aldosterone excess. Osteoporos Int. 2013; 24:2801–2807.
Article
58. Chhokar VS, Sun Y, Bhattacharya SK, Ahokas RA, Myers LK, Xing Z, et al. Loss of bone minerals and strength in rats with aldosteronism. Am J Physiol Heart Circ Physiol. 2004; 287:H2023–H2026.
Article
59. Chhokar VS, Sun Y, Bhattacharya SK, Ahokas RA, Myers LK, Xing Z, et al. Hyperparathyroidism and the calcium paradox of aldosteronism. Circulation. 2005; 111:871–878.
Article
60. Gupta M, Cheung CL, Hsu YH, Demissie S, Cupples LA, Kiel DP, et al. Identification of homogeneous genetic architecture of multiple genetically correlated traits by block clustering of genome-wide associations. J Bone Miner Res. 2011; 26:1261–1271.
Article
61. Koh JM, Khang YH, Jung CH, Bae S, Kim DJ, Chung YE, et al. Higher circulating hsCRP levels are associated with lower bone mineral density in healthy pre- and postmenopausal women: evidence for a link between systemic inflammation and osteoporosis. Osteoporos Int. 2005; 16:1263–1271.
Article
62. Cauley JA, Danielson ME, Boudreau RM, Forrest KY, Zmuda JM, Pahor M, et al. Inflammatory markers and incident fracture risk in older men and women: the Health Aging and Body Composition Study. J Bone Miner Res. 2007; 22:1088–1095.
Article
63. Stehr CB, Mellado R, Ocaranza MP, Carvajal CA, Mosso L, Becerra E, et al. Increased levels of oxidative stress, subclinical inflammation, and myocardial fibrosis markers in primary aldosteronism patients. J Hypertens. 2010; 28:2120–2126.
Article